1. Home
  2. Analysis
  3. Rescriptor
  4. Weakness

Rescriptor and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Rescriptor (delavirdine mesylate), especially for people who are male, 40-49 old, also take Norvir, and have Hiv infection.

The phase IV clinical study analyzes which people have Weakness when taking Rescriptor. It is created by eHealthMe based on reports of 426 people who have side effects when taking Rescriptor from the FDA, and is updated regularly.

What is Rescriptor?

Rescriptor has active ingredients of delavirdine mesylate. eHealthMe is studying from 426 Rescriptor users. Check the latest studies of Rescriptor.

What is Weakness?

Weakness is found to be associated with 3,642 drugs and 6,611 conditions by eHealthMe. Check the latest studies of Weakness.

On Jul, 10, 2026

426 people reported to have side effects when taking Rescriptor.
Among them, 18 people (4.23%) have Weakness.

Could Rescriptor cause Weakness?

Among these 18 people:

What is the gender of people who have Weakness when taking Rescriptor? *

  • female: 44.44 %
  • male: 55.56 %

What is the age of people who have Weakness when taking Rescriptor? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 33.33 %
  • 40-49: 40.0 %
  • 50-59: 13.33 %
  • 60+: 13.33 %

What are other drugs people take besides Rescriptor? *

  1. Norvir: 7 people, 38.89%
  2. Viramune: 5 people, 27.78%
  3. Kaletra: 5 people, 27.78%
  4. Fuzeon: 5 people, 27.78%
  5. Klonopin: 5 people, 27.78%
  6. Viread: 5 people, 27.78%
  7. Viracept: 4 people, 22.22%
  8. Fortovase: 4 people, 22.22%
  9. Combivir: 4 people, 22.22%
  10. Lisinopril: 4 people, 22.22%

What are other side effects people have besides Weakness? *

  1. Fatigue (feeling of tiredness): 6 people, 33.33%
  2. Stress And Anxiety: 6 people, 33.33%
  3. Nausea (feeling of having an urge to vomit): 5 people, 27.78%
  4. Anhedonia (inability to experience pleasure from activities usually found enjoyable): 4 people, 22.22%
  5. Dizziness: 4 people, 22.22%
  6. Pain: 4 people, 22.22%
  7. Emotional Distress: 4 people, 22.22%
  8. Bone Density Decreased: 3 people, 16.67%
  9. Hypoaesthesia (reduced sense of touch or sensation): 3 people, 16.67%
  10. Neck Pain: 3 people, 16.67%

What are the existing conditions these people have? *

  1. Hiv Infection: 5 people, 27.78%
  2. Sinusitis (inflammation of sinus): 2 people, 11.11%

* Approximation only. Some reports may have incomplete information.

Do you take Rescriptor and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rescriptor:

Weakness treatments and more:

How severe was Weakness and when was it recovered:

Expand to all the drugs that have ingredients of delavirdine mesylate:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Rescriptor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Browse all the conditions that are associated with Weakness:

How the study uses the data?

The study uses data from the FDA. It is based on delavirdine mesylate (the active ingredients of Rescriptor) and Rescriptor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.